PBH

Analyst Note: PBH (Prestige Consumer Healthcare Inc.)

Date: 2026-06-13 Current Price: $46.97

1. Structural Readiness

Aggressive/Pre-Breakout Entry: N/A (Current price is holding above support, but no confirmed breakout signal has triggered) Breakout Level: Not yet defined (Pending confirmation of the structural high that defines the coil top) Current Price: $46.97 Extension: N/A (Price has not yet extended from a confirmed breakout level) ATR Current: 4.2% (High volatility bucket)

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Thesis: None named at this date.

Analysis: There is no named macro or secular thesis driving this specific setup as of June 13, 2026. This is a tactical, setup-led name. The conviction must be derived entirely from the quality of the structural setup (the forming coil) and the underlying business fundamentals. We are not assigning a "growth" or "value" label based on a macro narrative, but rather evaluating the company's ability to execute its operational plan and the technical structure's readiness to capture that value.

3. The Business

Company Overview: Prestige Consumer Healthcare Inc. (PBH) operates as a manufacturer, marketer, and distributor of well-recognized, over-the-counter (OTC) health and personal care products. The company serves mass merchandisers, drug stores, food/dollar/convenience stores, club stores, and e-commerce channels in North America (US and Canada) and select international markets, including Australia.

Business Model & Segments: The business is structured into two principal areas:

• North American Over-the-Counter Healthcare: Includes brands such as Dramamine, Fleet, Hydralyte, Summer's Eve, Monistat, Breathe Right, and Dimetapp.
• International Over-the-Counter Healthcare: Includes brands like Gaviscon and Luden's.

Key Operational Highlights (as of source dates ≤ 2026-06-13):

• Revenue Guidance: Management forecasts fiscal '27 revenues of $1.1 billion to $1.12 billion, targeting organic growth of 1% to 3%.
• Product Recovery & Growth:
• Clear Eyes: Management expects growth in fiscal '27, driven by a "meaningful increase in production" ramped entirely in the back half of the year. This follows a period of supply constraints.
• GI Franchises: Dramamine, Fleet, and Hydralyte reported solid success in fiscal '26, with all brands growing.
• Women's Health: Summer's Eve showed stabilization, and Monistat held share in a category that has declined significantly over the past three years.
• Strategic Acquisitions:
• Pillar5 Pharma: Completed on December 18, 2025. This acquisition of a leading sterile ophthalmic manufacturer (and current Clear Eyes supplier) was funded via cash on hand and the asset-based revolving credit facility. This addresses the supply chain bottlenecks previously noted.
• Foundation Consumer Brands: A definitive agreement was entered into to acquire Breathe Right® and Dimetapp® brands, anticipated to close in the first half of fiscal 2027.
• Financial Position:
• Free Cash Flow: Management anticipates FCF of $250 million or more in fiscal '27.
• Adjusted EPS: Forecasted at $4.42 to $4.51 for fiscal '27.
• Liquidity: As of December 31, 2025, the company had a borrowing capacity of $146.4 million and was in compliance with all financial covenants.
• Customer Concentration: Walmart accounted for ~20% of gross revenues in 2026, and Amazon accounted for ~15%. Major brands accounted for ~83.5% of total revenues.

4. Archetype and Conviction

Archetype: Growth Leader (with elements of Operational Turnaround)

Fit Analysis: PBH fits the Growth Leader archetype not because of a speculative narrative, but because of a clear operational inflection point. The company is transitioning from a period of supply-constrained growth (fiscal '25/'26 shortages) to a period of capacity expansion and strategic acquisition.

• Margin Inflector: The acquisition of Pillar5 Pharma (a manufacturer) moves the company up the value chain for its Clear Eyes franchise, potentially improving margins and securing supply.
• Structural Quality: The business model is low-cost and leverages high consumer awareness (83.5% of revenue from top brands). The "recurring consumer needs" nature of the portfolio (pain relief, vision care, motion sickness) provides defensive characteristics.
• Valuation Context: Forward consensus EPS for FY1 is $4.54. At a current price of $46.97, the stock trades at approximately 10.3x forward earnings. This valuation is supported by the management's guidance of $4.42–$4.51 EPS and the anticipated FCF generation of $250M+.

Conviction Stack:

• Thesis Strength: Moderate (Tactical, no macro tailwinds).
• Evidence Quality: High. Management has provided specific, quantified guidance on revenue, EPS, and FCF, alongside clear timelines for supply ramp-ups and acquisitions.
• Structural Quality: The forming coil indicates a market that is digesting the recent acquisition news and supply recovery. The high ATR (4.2%) suggests active participation and volatility, which is necessary for a breakout.
• Setup Readiness: Partial. The structure is in place (Forming), but the breakout has not fired.
• Rerating Potential: Moderate. The rerating will depend on the successful execution of the Clear Eyes production ramp and the closing of the Foundation Consumer Brands deal.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: A failure to ramp Clear Eyes production in the back half of fiscal '27 as guided, or a significant delay in the Foundation Consumer Brands acquisition closing.
• Operational: A recurrence of the supply shortages that plagued fiscal '25/'26, leading to lost shelf space or customer relationships.

What Would Strengthen the Case:

• Fundamental: Management raising fiscal '27 guidance for revenue or EPS, or confirming the successful ramp of Clear Eyes production ahead of schedule.
• Strategic: Successful integration of Pillar5 Pharma leading to immediate margin expansion.

Gaps in Evidence:

• Acquisition Price: The specific purchase price or deal terms for the Foundation Consumer Brands acquisition are not detailed in the provided text.
• International Growth: While international sales are growing (16.1% in 2026), specific growth rates for the international segment are not provided in the evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management guidance for $1.1B-$1.12B revenue and $4.42-$4.51 EPS in fiscal '27; Clear Eyes production ramp scheduled for back half of year; Pillar5 acquisition completed to secure supply chain. Sizing hint: Position size should be conservative until the forming coil confirms a breakout; current volatility (4.2% ATR) requires careful risk management. Expected path: Management executes the Clear Eyes production ramp and closes the Foundation acquisition; price consolidates within the forming coil range until a breakout signal is triggered. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).